Belite Bio Q2 2023 Earnings Report $66.70 -0.15 (-0.22%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Belite Bio EPS ResultsActual EPS-$0.26Consensus EPS -$0.23Beat/MissMissed by -$0.03One Year Ago EPSN/ABelite Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABelite Bio Announcement DetailsQuarterQ2 2023Date8/8/2023TimeAfter Market ClosesConference Call ResourcesConference Call TranscriptSlide DeckPress ReleaseBLTE Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Belite Bio Earnings HeadlinesBelite Bio, Inc. Appoints New AuditorMarch 28 at 5:07 PM | tipranks.comBelite Bio price target raised to $80 from $79 at BenchmarkMarch 27, 2025 | markets.businessinsider.comThis trading frustration almost made me quitThis happened to me time and time again, and I wanted no more of it. That’s exactly why I set out to refine my strategy… And with the help of my good friend Nate, we have done exactly that… Now, I cannot promise future returns or against losses, but the real trades so far have been nothing but astounding. Turning my once 69% win rate, into 83.3% on real trades in the last two months. And instead of just telling you, I want to SHOW you. March 31, 2025 | WealthPress (Ad)Belite Bio's (BLTE) Buy Rating Reaffirmed at BenchmarkMarch 27, 2025 | americanbankingnews.comQ1 Earnings Forecast for Belite Bio Issued By HC WainwrightMarch 22, 2025 | americanbankingnews.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in FebruaryMarch 21, 2025 | americanbankingnews.comSee More Belite Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Belite Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Belite Bio and other key companies, straight to your email. Email Address About Belite BioBelite Bio (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.View Belite Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
